专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07932262B2 Quinazolines for PDK1 inhibition 失效
标题翻译：喹唑啉用于PDK1抑制
公开(公告)号：US07932262B2
公开(公告)日：2011-04-26
申请号：US12295967
申请日：2007-04-05
申请人： Savithri Ramurthy , Xiaodong Lin , Sharadha Subramanian , Alice Rico , Xiaojong M. Wang , Rama Jain , Jeremy M. Murray , Stephen E. Basham , Robert L. Warne , Wei Shu , Yasheen Zhou , Jeffrey Dove , Mina Aikawa , Payman Amiri , Weibo Wang , Johanna M. Jansen , Allan S. Wagman , Keith B. Pfister , Simon Ng
发明人： Savithri Ramurthy , Xiaodong Lin , Sharadha Subramanian , Alice Rico , Xiaojong M. Wang , Rama Jain , Jeremy M. Murray , Stephen E. Basham , Robert L. Warne , Wei Shu , Yasheen Zhou , Jeffrey Dove , Mina Aikawa , Payman Amiri , Weibo Wang , Johanna M. Jansen , Allan S. Wagman , Keith B. Pfister , Simon Ng
IPC分类号： A61K31/517
CPC分类号： C07D239/94 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D451/06 , C07D453/02
摘要： The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
摘要翻译：本发明提供作为PDK1抑制剂的喹唑啉化合物。还提供了包含该化合物的药物组合物，以及用化合物或组合物治疗增殖性疾病如癌症的方法。

2. 发明申请

US20100048561A1 QUINAZOLINES FOR PDK1 INHIBITION 失效
标题翻译：用于PDK1抑制剂的喹唑啉
公开(公告)号：US20100048561A1
公开(公告)日：2010-02-25
申请号：US12295967
申请日：2007-04-05
申请人： Savithri Ramurthy , Xiaodong Lin , Sharadha Subramanian , Alice C. Rico , Xiaojing M. Wang , Rama Jain , Jeremy M. Murray , Steven E. Basham , Robert L. Warne , Wei Shu , Yasheen Zhou , Jeffrey Dove , Mina Aikawa , Payman Amiri , Weibo Wang , Johanna M. Jansen , Allan S. Wagman , Keith B. Pfister , Simon Ng
发明人： Savithri Ramurthy , Xiaodong Lin , Sharadha Subramanian , Alice C. Rico , Xiaojing M. Wang , Rama Jain , Jeremy M. Murray , Steven E. Basham , Robert L. Warne , Wei Shu , Yasheen Zhou , Jeffrey Dove , Mina Aikawa , Payman Amiri , Weibo Wang , Johanna M. Jansen , Allan S. Wagman , Keith B. Pfister , Simon Ng
IPC分类号： A61K31/517 , C07D401/12 , C07D401/14 , C07D239/84 , C07D413/14 , A61K31/5377 , A61P35/00
CPC分类号： C07D239/94 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D451/06 , C07D453/02
摘要： The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
摘要翻译：本发明提供作为PDK1抑制剂的喹唑啉化合物。还提供了包含该化合物的药物组合物，以及用化合物或组合物治疗增殖性疾病如癌症的方法。

3. 发明申请

US20100216767A1 QUINAZOLINES FOR PDK1 INHIBITION 审中-公开
标题翻译：用于PDK1抑制剂的喹唑啉
公开(公告)号：US20100216767A1
公开(公告)日：2010-08-26
申请号：US12448390
申请日：2007-12-20
申请人： Mina Aikawa , Payman Amiri , Steven Bashman , Jeffrey Dove , Rama Jain , Xiaodong Lin , Jeremy Murray , Savithri Ramurthy , Alice Rico , Wei Shu , Sharadha Subramanian , Xiaojing Michael Wang , Robert L. Warne , Yasheen Zhou
发明人： Mina Aikawa , Payman Amiri , Steven Bashman , Jeffrey Dove , Rama Jain , Xiaodong Lin , Jeremy Murray , Savithri Ramurthy , Alice Rico , Wei Shu , Sharadha Subramanian , Xiaojing Michael Wang , Robert L. Warne , Yasheen Zhou
IPC分类号： A61K31/337 , C07D239/84 , A61K31/517 , C07D401/12 , A61K31/496 , C07D403/10 , C07D413/10 , A61K31/5377 , C07D413/14 , C07D403/12 , A61P35/00
CPC分类号： C07D239/84 , C07D401/08 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D411/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14
摘要： The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
摘要翻译：本发明提供了作为PDK1抑制剂的新型化合物。还提供了包含该化合物的药物组合物，以及用化合物或组合物治疗增殖性疾病如癌症的方法。

4. 发明申请

US20070161680A1 Substituted benzimidazoles and methods of their use 有权
标题翻译：取代的苯并咪唑及其使用方法
公开(公告)号：US20070161680A1
公开(公告)日：2007-07-12
申请号：US11513959
申请日：2006-08-30
申请人： Mina Alkawa , Payman Amiri , Jeffrey Dove , Barry Levine , Christopher McBride , Teresa Pick , Daniel Poon , Savithri Ramurthy , Paul Renhowe , Cynthia Shafer , Darrin Stuart , Sharadha Subramanian
发明人： Mina Alkawa , Payman Amiri , Jeffrey Dove , Barry Levine , Christopher McBride , Teresa Pick , Daniel Poon , Savithri Ramurthy , Paul Renhowe , Cynthia Shafer , Darrin Stuart , Sharadha Subramanian
IPC分类号： A61K31/4439 , C07D403/14
CPC分类号： C07D401/14 , Y02P20/55
摘要： New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.
摘要翻译：提供了新的取代的苯并咪唑化合物，组合物和抑制与人或动物受试者的肿瘤发生相关的激酶活性的方法。在某些实施方案中，化合物和组合物有效地抑制至少一种丝氨酸/苏氨酸激酶或受体酪氨酸激酶的活性。新化合物和组合物可以单独使用或与至少一种另外的药剂组合使用，用于治疗丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的病症，例如癌症。

5. 发明申请

US20060217805A1 Treatment of bioprosthetic tissues to mitigate post implantation calcification 有权
公开(公告)号：US20060217805A1
公开(公告)日：2006-09-28
申请号：US11387615
申请日：2006-03-23
申请人： Jeffrey Dove
发明人： Jeffrey Dove
IPC分类号： A61F2/52
CPC分类号： A61L27/3683 , A61L27/3604 , A61L2400/02
摘要： The present invention provides methods for treating tissue to inhibit post-implant calcification of a biological tissue. In one method of this invention, a tissue is immersed in or otherwise contacted with a pretreated glutaraldehyde solution, i.e., a heat-treated or pH-adjusted glutaraldehyde solution. The tissue may be partially fixed with glutaraldehyde prior to, after, or concurrently with the step of contacting the tissue with the pretreated gluteraldehyde. Contact with the pretreated gluteraldehyde produces free amine groups on the tissue, which are subsequently blocked by contacting the crosslinked tissue with a blocking agent. In another embodiment, a tissue is contacted with either a non-pretreated glutaraldehyde or a pH-adjusted glutaraldehyde solution for a period of time sufficient to crosslink the tissue. The crosslinked tissue is then treated with a reducing agent that reduces aldehyde and carboxylic acid groups on the fixed tissue.

6. 发明授权

US06613838B1 Synthetic rubber elastomers as replacements for natural rubber latex 有权
标题翻译：合成橡胶弹性体作为天然橡胶胶乳的替代品
公开(公告)号：US06613838B1
公开(公告)日：2003-09-02
申请号：US09651142
申请日：2000-08-30
申请人： Jeffrey Dove
发明人： Jeffrey Dove
IPC分类号： C08L5302
CPC分类号： C08L53/025 , C08L2666/24 , C08L2666/02
摘要： A nonallergenic synthetic rubber elastomer having physical qualities equal to or superior to natural rubber latex is provided. The synthetic rubber elastomer is composed of at least one high molecular weight hydrogenated tri-block thermoplastic elastomer (HTPE), at least one low molecular weight HTPE and a crosslinkable cyclic unsaturated polyolefin crystalline polymer. Articles are formed from the synthetic rubber elastomers and then exposed to crosslinking agents. The articles thus formed possess physical qualities equal to or superior to natural rubber latex and improved biocompatability.
摘要翻译：提供具有等于或优于天然橡胶胶乳的物理性质的非变应性合成橡胶弹性体。合成橡胶弹性体由至少一种高分子量氢化三嵌段热塑性弹性体（HTPE），至少一种低分子量HTPE和可交联的环状不饱和聚烯烃结晶聚合物组成。制品由合成橡胶弹性体形成，然后暴露于交联剂。如此形成的制品具有等于或优于天然橡胶胶乳的物理特性，并提高生物相容性。

7. 发明申请

US20110165675A1 CAPPING BIOPROSTHETIC TISSUE TO REDUCE CALCIFICATION 有权
标题翻译： CAPPING BIOPROSTHETIC TISSUE减少计算
公开(公告)号：US20110165675A1
公开(公告)日：2011-07-07
申请号：US12777994
申请日：2010-05-11
申请人： Jeffrey Dove , Darin Dobler , Jim Davidson , Gregory A. Wright
发明人： Jeffrey Dove , Darin Dobler , Jim Davidson , Gregory A. Wright
IPC分类号： C12N5/071 , C12N5/00
CPC分类号： A61F2/2415 , A61F2/0095 , A61F2/24 , A61F2/2412 , A61F2/2418 , A61L27/3604 , A61L27/3625 , A61L27/3629 , A61L27/3687 , A61L27/3691 , A61L27/507 , A61L2400/02 , A61L2430/20
摘要： A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
摘要翻译：用于植入物或组装的生物假体心脏瓣膜中用于减少体内钙化的生物假体组织的治疗。该方法包括将钙化缓解剂如封端剂或抗氧化剂施用于组织以特异性抑制组织中的氧化。此外，该方法可用于抑制脱水组织中的氧化。封端剂抑制由氧化暴露或产生的组织中的结合位点的形成，否则在植入时会吸引钙，磷酸盐，免疫原性因子或钙化的其它前体。在一种方法中，组装的生物假体心脏瓣膜中的组织小叶在脱水和灭菌之前用醛封端剂预处理。

8. 发明申请

US20060217804A1 Treatment of bioprosthetic tissues to mitigate post implantation calcification 审中-公开
公开(公告)号：US20060217804A1
公开(公告)日：2006-09-28
申请号：US11387606
申请日：2006-03-23
申请人： Jeffrey Dove
发明人： Jeffrey Dove
IPC分类号： A61F2/52
CPC分类号： A61L27/38 , A61L27/3604 , A61L27/3687 , A61L27/54 , A61L2300/252 , A61L2400/02
摘要： The present invention provides methods for treating tissue to inhibit post-implant calcification of a biological tissue. In one method of this invention, a tissue is immersed in or otherwise contacted with a pretreated glutaraldehyde solution, i.e., a heat-treated or pH-adjusted glutaraldehyde solution. The tissue may be partially fixed with glutaraldehyde prior to, after, or concurrently with the step of contacting the tissue with the pretreated gluteraldehyde. Contact with the pretreated gluteraldehyde produces free amine groups on the tissue, which are subsequently blocked by contacting the crosslinked tissue with a blocking agent. In another embodiment, a tissue is contacted with either a non-pretreated glutaraldehyde or a pH-adjusted glutaraldehyde solution for a period of time sufficient to crosslink the tissue. The crosslinked tissue is then treated with a reducing agent that reduces aldehyde and carboxylic acid groups on the fixed tissue.

9. 发明申请

US20050196331A1 Hazardous vapor mitigation system 审中-公开
标题翻译：危险气体减缓系统
公开(公告)号：US20050196331A1
公开(公告)日：2005-09-08
申请号：US10861296
申请日：2004-06-04
申请人： Jeffrey Dove
发明人： Jeffrey Dove
IPC分类号： B01J19/12
CPC分类号： B01D53/002 , Y02A50/235
摘要： A process for removing volatile organic compounds (VOCS) from hazardous waste vapor emitted during liquid hazardous waste clean up and the device for removing volatile organic compounds therein is provided. The process described herein comprises cooling the VOC-laden air stream sufficiently to allow condensation of solvents, passage of the air stream through an ozone-containing environment in the presence of ultraviolet light and finally passage of the air stream through an absorbent filter.
摘要翻译：提供了一种从液体危险废物清理过程中排出的危险废物蒸气中除去挥发性有机化合物（VOCS）的方法和用于除去挥发性有机化合物的装置。本文所述的方法包括充分冷却载有VOC的空气流以使溶剂冷凝，在紫外线下使空气流通过含臭氧的环境，并最终使空气流通过吸收过滤器。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式